BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone415-506-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.49 billion
Profitability
Miscellaneous
Employees2,849
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable
BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions
What is BioMarin Pharmaceutical's stock symbol?
BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."
How were BioMarin Pharmaceutical's earnings last quarter?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its earnings results on Thursday, August, 1st. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.16. The biotechnology company earned $388 million during the quarter, compared to analyst estimates of $415.03 million. BioMarin Pharmaceutical had a negative net margin of 7.19% and a negative return on equity of 3.12%. The business's revenue was up 4.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.09) earnings per share. View BioMarin Pharmaceutical's Earnings History.
When is BioMarin Pharmaceutical's next earnings date?
What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?
BioMarin Pharmaceutical issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.68-1.75 billion, compared to the consensus revenue estimate of $1.7 billion.
What price target have analysts set for BMRN?
16 Wall Street analysts have issued 12 month price targets for BioMarin Pharmaceutical's stock. Their predictions range from $81.00 to $133.00. On average, they anticipate BioMarin Pharmaceutical's stock price to reach $115.3333 in the next year. This suggests a possible upside of 53.9% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical.
What is the consensus analysts' recommendation for BioMarin Pharmaceutical?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical.
What are Wall Street analysts saying about BioMarin Pharmaceutical stock?
Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our OW and $131 PT. We continue to see highly favorable risk/reward ahead of key pipeline updates over the next 12 months. BioMarin reported an in-line quarter, although the overwhelming focus of the call was on valrox (hemophilia A gene therapy). The valrox 3-year update is on track for a top-line by early June (ISTH late-breaker submission due June 7). Not much new color on valrox from the call: management continues to sound confident in durability and potential for accelerated pathway (BMRN’s filing decision by YE19). For investors, we think valrox is more of a show-me story, which is why the update in June is important, although at this point somewhat of an overhang, in our view." (4/26/2019)
- 2. According to Zacks Investment Research, "BioMarin missed estimates for both earnings and sales in Q4. BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, on the back of strong demand trends. Its newest product, Palynziq’s U.S. launch is progressing well. Its rare disease pipeline is also progressing well. Growing pipeline focus toward gene therapy agents is encouraging However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Moreover, Naglazyme and Vimzin revenues vary on a quarterly basis, primarily owing to infrequent ordering patterns from some countries, mainly Brazil. Meanwhile, BioMarin is facing a generic threat for Kuvan in 2020. The earlier-than-expected entry of generics will be a huge blow for the company." (3/1/2019)
Has BioMarin Pharmaceutical been receiving favorable news coverage?
Press coverage about BMRN stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a news impact score of -1.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for BioMarin Pharmaceutical.
Who are some of BioMarin Pharmaceutical's key competitors?
Some companies that are related to BioMarin Pharmaceutical include Vertex Pharmaceuticals (VRTX), Shiseido (SSDOY), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Mylan (MYL), Array Biopharma (ARRY), Elanco Animal Health (ELAN) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of BioMarin Pharmaceutical own?
Who are BioMarin Pharmaceutical's key executives?
BioMarin Pharmaceutical's management team includes the folowing people:
- Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)
- Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)
- Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)
- Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)
- Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61)
Who are BioMarin Pharmaceutical's major shareholders?
BioMarin Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.89%), Primecap Management Co. CA (7.96%), Jennison Associates LLC (5.26%), Nuveen Asset Management LLC (1.68%), Viking Global Investors LP (1.44%) and Price T Rowe Associates Inc. MD (1.28%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.
Which major investors are selling BioMarin Pharmaceutical stock?
BMRN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Viking Global Investors LP, Verition Fund Management LLC, Waddell & Reed Financial Inc., Highline Capital Management L.P., Victory Capital Management Inc., Price T Rowe Associates Inc. MD and Manning & Napier Group LLC. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.
Which major investors are buying BioMarin Pharmaceutical stock?
BMRN stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, York Capital Management Global Advisors LLC, DekaBank Deutsche Girozentrale, Bessemer Group Inc., Marshall Wace LLP, Point72 Asset Management L.P., Vanguard Group Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for BioMarin Pharmaceutical.
How do I buy shares of BioMarin Pharmaceutical?
Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BioMarin Pharmaceutical's stock price today?
One share of BMRN stock can currently be purchased for approximately $74.95.
How big of a company is BioMarin Pharmaceutical?
BioMarin Pharmaceutical has a market capitalization of $13.45 billion and generates $1.49 billion in revenue each year. The biotechnology company earns $-77,210,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. BioMarin Pharmaceutical employs 2,849 workers across the globe.View Additional Information About BioMarin Pharmaceutical.
What is BioMarin Pharmaceutical's official website?
How can I contact BioMarin Pharmaceutical?
BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]
MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
